Clinical trials: Resolution
Healthy Subjects (HS)
Safety and Tolerability, and PK of Sibeprenlimab in Chinese Healthy Subject
A Trial to Assess the Pharmacokinetics, Safety and Tolerability, and Pharmacodynamics, of Sibeprenlimab Solution Administered Subcutaneously in Chinese Healthy Subjects
- Trial name
- NCT07105124
- Testing
- Sibeprenlimab
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Otsuka Beijing Research Institute
Androgenetic Alopecia
A Study Evaluating the Efficacy and Safety of SM04554 Topical Solution in Male Subjects With Androgenetic Alopecia
This multi-center, randomized, double-blind, placebo-controlled study, conducted in Turkey, will assess the efficacy and safety of topical SM04554 solution (0.15% and 0.25%) applied daily to the scalp of male androgenetic…
- Trial name
- NCT03742518
- Testing
- Topical SM04554 0.15% solution, Topical SM04554 0.25% solution, Topical vehicle solution
- Where
- 14 sites in Turkey (Türkiye)
- Volunteers
- 675 people
- Sponsor
- Biosplice Therapeutics, Inc.
End Stage Renal Disease (ESRD)
Performance Evaluation of the AMIA APD Solution Generation System in Patients End Stage Renal Disease (ESRD)
Peritoneal dialysis (PD) is a well-established treatment for renal failure including long-term management of end stage renal disease (ESRD) by continuous ambulatory peritoneal dialysis or automated peritoneal dialysis (APD).
- Trial name
- NCT03812679
- Testing
- AMIA APD Solution Generation System
- Where
- 11 sites in United States
- Volunteers
- 22 people
- Sponsor
- Vantive Health LLC
Healthy
Metabolism and Pharmacokinetics of [14C]-BI 44370 BS Administered as an Oral Solution in Healthy Male Volunteers
Study to investigate the basic pharmacokinetics of BI 44370 BS, its metabolite CD 10419 BS, and 14C-radioactivity including mass balance, excretion pathways, and metabolism following a single oral administration of 200 mg [14C]BI…
- Trial name
- NCT02215772
- Testing
- BI 44370 BS
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
A Study of Sublingually Administered (S)-Ketamine Oral Solution in Healthy Participants
The purpose of this study is to characterize the plasma pharmacokinetic (PK) profile following the single ascending dose (SAD) levels of an (S)-ketamine oral solution for sublingual administration in healthy participants.
- Trial name
- NCT04282746
- Testing
- JNJ-54135419
- Where
- Belgium
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Allergic Conjunctivitis
Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Allergic Conjunctivitis.
The purpose of this study is to establish the safety and efficacy of ketotifen/naphazoline ophthalmic solution compared to vehicle and its individual components in alleviating the signs and symptoms of conjunctival allergen…
- Trial name
- NCT00769886
- Testing
- Ketotifen/naphazoline, Ketotifen, Naphazoline
- Where
- United States
- Volunteers
- 144 people
- Sponsor
- Bausch & Lomb Incorporated
Dry Eye
ALY688 Ophthalmic Solution in Subjects With Dry Eye Disease
Study Evaluating the Safety and Efficacy of Two Concentrations (0.4% and 1%) of ALY688 Ophthalmic Solution in Subjects with Dry Eye Disease
- Trial name
- OASIS-1 (NCT04899518)
- Testing
- ALY688 Ophthalmic Solution
- Where
- United States
- Volunteers
- 922 people
- Sponsor
- Allysta Pharmaceutical
Night Vision Complaints, Decrease in Night Vision
The Safety and Efficacy of Phentolamine Mesylate Ophthalmic Solution in Subjects With Severe Night Vision Disturbances
The objectives of this study are: To evaluate the efficacy of phentolamine mesylate 0.5% and 1.0% ophthalmic solution (Nyxol) in the treatment of night vision complaints, including reduced contrast sensitivity To evaluate the…
- Conditions
- Night Vision Complaints, Decrease in Night Vision, Disturbance; Vision, Loss
- Trial name
- NCT01703559
- Testing
- Phentolamine Mesylate Ophthalmic Solution 1.0%, Phentolamine Mesylate Ophthalmic Solution 0.5%
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Opus Genetics, Inc
Nail Psoriasis
Study to Evaluate the Efficacy and Safety of P-3073 Nail Solution in the Treatment of Mild to Moderate Psoriatic Fingernail/s
The objective of this phase III study is to evaluate the efficacy, systemic safety and local tolerability of P-3073 (calcipotriene 0.005%) nail solution in patients with mild to moderate psoriatic fingernail/s.
- Trial name
- NCT03079973
- Testing
- P-3073 (calcipotriene 0.005%), Vehicle of P-3073
- Where
- 58 sites in United States
- Sponsor
- Polichem S.A.
Healthy Male Chinese Volunteers
A Study to Investigate the Bioequivalence of Lacosamide 200mg Administered as Intravenous Solution and Oral Tablet in Healthy Chinese Male Subjects
The purpose of this study is to assess the bioequivalence of a 200 mg single dose Lacosamide (LCM) intravenous (iv) solution with a 200 mg single dose LCM oral tablet in healthy Chinese male subjects.
- Trial name
- NCT03204474
- Testing
- Lacosamide (LCM) tablet, Lacosamide (LCM) solution for infusion
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- UCB Biopharma S.P.R.L.
Telemedicine, Gait, Hemiplegic
Treatment of Hemiparetic Gait Impairments Using Telehealth With the Moterum iStride Solution™
The objective of this research is to investigate the feasibility of delivering gait treatment using the Moterum iStride Solution™ to individuals with hemiparetic gait impairments using a telemedicine modality, the Moterum Digital…
- Conditions
- Telemedicine, Gait, Hemiplegic, Gait Disorders, Neurologic, Stroke
- Trial name
- NCT04434313
- Testing
- Delivery of iStride™ device gait treatment using telemedicine
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Moterum Technologies, Inc.
Cataract, Glaucoma
Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhone)
This trial is a randomized study to evaluate the Bimatoprost Implant System used in combination with the SpyGlass IOL to Timolol Ophthalmic Solution in participants with mild to moderate open-angle glaucoma or ocular hypertension…
- Conditions
- Cataract, Glaucoma, Ocular Hypertension
- Trial name
- NCT07218796
- Testing
- Bimatoprost Implant System, SpyGlass IOL, Timolol Maleate Ophthalmic Solution, 0.5%
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- SpyGlass Pharma, Inc.
Eye Diseases
Next Generation Ophthalmic Irrigating Solution Posterior Segment Study
The purpose of this study is to evaluate the safety of Next Generation Ophthalmic Irrigating Solution (NGOIS) compared to BSS PLUS for use during surgery for removal of epimacular membrane and vitrectomy.
- Trial name
- NCT00333203
- Testing
- Next Generation Ophthalmic Irrigating Solution (NGOIS), BSS Plus
- Where
- United States
- Volunteers
- 369 people
- Sponsor
- Alcon Research
Healthy Volunteer Subjects
A Study to Establish Safety and Maximum Tolerated Dose of IV Trehalose in Healthy Subjects
This will be a double-blind, randomized, placebo-controlled, single ascending dose study performed in healthy subjects. The study will include up to four escalating dose cohorts with eight (8) subjects in each cohort.
- Trial name
- NCT02725957
- Testing
- Trehalose for IV Infusion, Saline 0.9% IV
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Bioblast Pharma Ltd.
Healthy
An Open Label, Study of the Systemic Exposure to Articaine After Topical Ocular Dosing of AG-920
This is a Phase 1, open-label, non-comparative study in healthy subjects performed in the US. It is designed to assess systemic exposure to articaine and its metabolite articainic acid after dosing a single topical ocular…
- Trial name
- NCT04759339
- Testing
- AG-920
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- American Genomics, LLC
HIV Infections
A Phase I/II Clinical Study of WF 10 IV Solution ( TCDO ) in Patients With HIV Infection
To evaluate the clinical toxicity, safety, and MTD of WF 10 ( TCDO ) intravenous solution administered to patients with HIV infection. To evaluate the potential anti-HIV activity of TCDO.
- Trial name
- NCT00002119
- Testing
- WF10
- Where
- United States
- Sponsor
- Oxo Chemie GmbH
Allergic Rhinoconjunctivitis
Multicenter Trial of Sublingual Immunotherapy With a Solution of Grass Pollen Allergen Extract in Children
Evaluation of safety and efficacy of sublingual immunotherapy with grass pollen allergens formulated as solution in comparison to a symptomatic standard treatment with add on placebo in grass pollen allergic children suffering…
- Trial name
- NCT00841256
- Testing
- Grass pollen allergens in a water/glycerol solution
- Where
- Germany
- Volunteers
- 207 people
- Sponsor
- Allergopharma GmbH & Co. KG
Cancer
Palliative Care Study in Patients With Advanced Cancer
The purpose of this study is to determine whether patients with advanced cancers who receive AVR118 solution for injection into the skin can achieve improvement in quality of life.
- Trial name
- NCT00127517
- Testing
- peptide-nucleic acid solution AVR118
- Where
- 3 sites in United States
- Sponsor
- Advanced Viral Research Corp
Nearsightedness, Near Sightedness
The Safety and Efficacy of SYD-101 in Children With Myopia
Myopia, or nearsightedness, is the most common eye disorder, often affecting more than 40% of adults in Europe, Asia and the USA.
- Conditions
- Nearsightedness, Near Sightedness, Near-sightedness
- Trial name
- STAR (NCT03918915)
- Testing
- SYD-101 0.01%, SYD-101 0.03%, Vehicle
- Where
- 47 sites in United States, Austria and 1 more
- Volunteers
- 852 people
- Sponsor
- Sydnexis, Inc.
SARS-CoV Infection
Nitric Oxide Releasing Solution to Treat and Prevent Exacerbation of Mild COVID-19 Infection
This is a double-blinded, placebo-controlled parallel, phase II clinical efficacy study evaluating Nitric Oxide Nasal Irrigation (NONI) for the treatment of COVID-19 in individuals with mild COVID-19 Infection.
- Trial name
- NCT04443868
- Testing
- Nitric Oxide-Releasing Drug
- Sponsor
- Sanotize Research and Development corp.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.